Inhibition of Endothelial Fak Activity Prevents Tumor Metastasis by Enhancing Barrier Function

Christine Jean,Xiao Lei Chen,Ju-Ock Nam,Isabelle Tancioni,Sean Uryu,Christine Lawson,Kristy K. Ward,Colin T. Walsh,Nichol L. G. Miller,Majid Ghassemian,Patric Turowski,Elisabetta Dejana,Sara Weis,David A. Cheresh,David D. Schlaepfer

DOI: https://doi.org/10.1083/jcb.201307067

2014-01-01

Abstract:Pharmacological focal adhesion kinase (FAK) inhibition prevents tumor growth and metastasis, via actions on both tumor and stromal cells. In this paper, we show that vascular endothelial cadherin (VEC) tyrosine (Y) 658 is a target of FAK in tumor-associated endothelial cells (ECs). Conditional kinase-dead FAK knockin within ECs inhibited recombinant vascular endothelial growth factor (VEGF-A) and tumor-induced VEC-Y658 phosphorylation in vivo. Adherence of VEGF-expressing tumor cells to ECs triggered FAK-dependent VEC-Y658 phosphorylation. Both FAK inhibition and VEC-Y658F mutation within ECs prevented VEGF-initiated paracellular permeability and tumor cell transmigration across EC barriers. In mice, EC FAK inhibition prevented VEGF-dependent tumor cell extravasation and melanoma dermal to lung metastasis without affecting primary tumor growth. As pharmacological c-Src or FAK inhibition prevents VEGF-stimulated c-Src and FAK translocation to EC adherens junctions, but FAK inhibition does not alter c-Src activation, our experiments identify EC FAK as a key intermediate between c-Src and the regulation of EC barrier function controlling tumor metastasis.